FDA ad­comm votes unan­i­mous­ly in sup­port of a J&J Covid-19 boost­er two months af­ter one-dose shot

The FDA’s Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee (VRB­PAC) on Fri­day vot­ed 19-0 in fa­vor of au­tho­riz­ing a sec­ond shot of J&J’s Covid-19 vac­cine to fol­low at least two months af­ter the ini­tial dose.

Reg­u­la­tors don’t have to fol­low VRB­PAC’s rec­om­men­da­tion, but they al­most al­ways do. Con­sid­er­ing that the CDC’s ad­vi­so­ry com­mit­tee has al­ready been set to re­view the ex­pand­ed EUA, VRB­PAC’s rec­om­men­da­tion is like­ly to be adopt­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.